Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.77 |
| ▸ | CLK1 | P49759 | 4/20 | 0.70 |
| ▸ | CLK2 | P49760 | 4/20 | 0.70 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.70 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.70 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.70 |
| ▸ | CLK3 | P49761 | 3/20 | 0.70 |
| ▸ | GSK3B | P49841 | 2/20 | 0.70 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.70 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.70 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.70 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.70 |
| ▸ | PIM1 | P11309 | 2/20 | 0.63 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.63 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.63 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.57 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354575 | 1.00 | FGFR1 (0.77) | FGFR1CLK1CLK2DYRK1ACLK4 | |
| SCHEMBL16935421 | 0.87 | FGFR1 (1.00) | FGFR1CLK1CLK2DYRK1ACLK4 | |
| SCHEMBL2455100 | 0.82 | GSK3B (1.00) | FGFR1CLK1CLK2DYRK1ACLK4 | |
| SCHEMBL1422720 | 0.82 | NPC1 (0.66) | FGFR1ALDH1A1 | |
| SCHEMBL4791316 | 0.81 | CLK1 (1.00) | FGFR1CLK1CLK2DYRK1ACLK4 | |
| SCHEMBL26260198 | 0.78 | CYP11B2 (0.88) | FGFR1CYP11B1CYP11B2CYP19A1CYP17A1 | |
| SCHEMBL14688781 | 0.78 | PIM1 (1.00) | FGFR1CLK2DYRK1ACLK3PIM1 | |
| SCHEMBL15651609 | 0.77 | MAPK1 (0.71) | FGFR1CLK1CLK2DYRK1ACLK4 | |
| SCHEMBL27074803 | 0.77 | GSK3B (0.70) | FGFR1CLK1CLK2DYRK1ACLK4 | |
| SCHEMBL6657347 | 0.77 | NPC1 (0.64) | FGFR1CYP11B1CYP11B2CYP19A1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358684-A1 | METHOD FOR ENHANCING INNATE IMMUNE RESPONSE | KYOTO UNIVERSITY (JP) | 2024-10-31 | — | — | US | disclosed |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | KYOTO UNIVERSITY (JP) | 2024-07-02 | — | — | US | disclosed |
| EP-4353260-A1 | METHOD FOR ENHANCING INNATE IMMUNE RESPONSE | Kyoto University (JP) | 2024-04-17 | — | — | EP | disclosed |
| US-20230272401-A1 | COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF | Genetic Intelligence, Inc | 2023-08-31 | — | — | US | disclosed |
| WO-2023081800-A1 | ALPHA-2A ADRENERGIC RECEPTOR MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-4129340-A1 | SUPPRESSION OF NEUROINFLAMMATION AND COMPOSITION AND METHOD THEREFOR | Kyoto University (JP) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022255411-A1 | METHOD FOR ENHANCING INNATE IMMUNE RESPONSE | 国立大学法人京都大学 | 2022-12-08 | — | — | WO | disclosed |
| WO-2022255411-A1 | METHOD FOR ENHANCING INNATE IMMUNE RESPONSE | 国立大学法人京都大学 | 2022-12-08 | — | — | WO | disclosed |
| US-11318126-B2 | Composition for activating neurogenesis | KYOTO UNIVERSITY (JP) | 2022-05-03 | — | — | US | disclosed |
| CN-113968859-A | Multi-element fused ring compound and application thereof in organic electroluminescent device | 北京鼎材科技有限公司 | 2022-01-25 | — | — | CN | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007098214-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| US-7232912-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20060111322-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2006-05-25 | — | — | US | disclosed |
| US-6919461-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030139463-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | REICH SIEGFRIED HEINZ (US) | 2003-07-24 | — | — | US | disclosed |
| US-6555539-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS | 2003-04-29 | — | — | US | disclosed |
| US-20020161022-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358684-A1 | METHOD FOR ENHANCING INNATE IMMUNE RESPONSE | IRF3, STING1, MYD88 | FGFR1 4661/4885CLK1 1295/4885CLK2 1617/4885 |
| US-20230272401-A1 | COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF | TARDBP, FUS, RBM17 | FGFR1 4458/4885CLK1 3177/4885CLK2 3367/4885 |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | RBM17, SFPQ, HNRNPAB | FGFR1 3261/4885CLK1 3184/4885CLK2 2309/4885 |
| US-20020161022-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | FGFR1 213/4885CLK1 545/4885CLK2 303/4885 |
| US-20030139463-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | FGFR1 213/4885CLK1 545/4885CLK2 303/4885 |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | FGFR1 2808/4885CLK1 1079/4885CLK2 668/4885 |
| US-11318126-B2 | Composition for activating neurogenesis | BDNF, GAP43, DCX | FGFR1 642/4885CLK1 839/4885CLK2 564/4885 |
| US-20060111322-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | MKI67, CCNI, CDK3 | FGFR1 550/4885CLK1 1474/4885CLK2 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.